Hypercapnia-Based Interventions for Parkinson's Disease

This trial tests new breathing treatments to help people with Parkinson's disease improve speech, breathing, and muscle control. Participants will engage in brief sessions of breathing higher carbon dioxide levels with either low or normal oxygen, known as Acute Intermittent Hypercapnic Hypoxia (AIHH) and Acute Intermittent Hypercapnic Normoxia (AIHN), respectively. The trial also seeks blood markers to identify who might benefit the most. It suits individuals with Parkinson's disease who can walk at least 10 feet and follow instructions. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance the quality of life for Parkinson's patients.

A previous study observed no harmful effects when people with Parkinson's disease experienced intermittent hypoxia, which involves breathing low oxygen levels for short periods. Another study found that this approach, known as acute intermittent hypoxia (AIH), was well-tolerated and did not cause treatment-related side effects.

Research also suggests that adding mild hypercapnia, an increase in carbon dioxide levels, can enhance some benefits of AIH. While these findings are promising, no randomized controlled trials have specifically examined how people with Parkinson’s disease respond to these combined exposures.

Researchers are excited about hypercapnia-based interventions for Parkinson's Disease because they offer a novel approach by utilizing controlled breathing techniques. Unlike standard treatments that primarily target dopamine regulation, these methods involve breathing in increased levels of carbon dioxide (CO2), either with low oxygen (hypoxia) or normal oxygen (normoxia), to potentially improve symptoms. This approach could stimulate the body's natural pathways to enhance neurological function and improve motor skills without relying on medication. By examining upper airway function, axial function, and blood biomarkers before and after treatment, researchers hope to uncover new insights into Parkinson's management.

This trial will compare two interventions for Parkinson's disease: Acute Intermittent Hypercapnic Hypoxia (AIHH) and Acute Intermittent Hypercapnic Normoxia (AIHN). Studies have shown that intermittent hypoxia, or occasionally having lower oxygen levels, might improve symptoms in people with Parkinson's disease. It could potentially enhance cognitive abilities and reduce certain disease-related markers. Research also suggests that combining higher carbon dioxide levels with low oxygen, as in AIHH, might better control movement. This combination has shown promising results, such as faster muscle response. Overall, early findings suggest these therapies could offer new ways to manage Parkinson's symptoms.¹²⁴⁶⁷